POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second ...

The Watertown, Massachusetts-based biotech had been evaluating the CHK1/2 inhibitor, called prexasertib or ACR-368, in a phase 2b trial of patients with endometrial cancer. These patients were ...

“We made important strides in 2024 as we became a public company and continued to advance BBI-355, our oral, selective CHK1 inhibitor in the Phase 1/2 POTENTIATE trial in patients with oncogene ...

Recently, the research team led by Wei Li and Chao Liu from Guangzhou Medical University Affiliated Women and Children's Medical Center, in ...

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies ...

Acrivon Therapeutics, Inc.’s ACRV share price has dipped by 11.25%, which has investors questioning if this is right time to ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials ...

Acrivon is currently advancing its lead candidate, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial ...

I place far more faith on the phenomenal amount of work she has carried out on CHK 1 inhibitors which include 737 and Prexasertib ( Prexasertib is a Chk1/2 inhibitor. Resistance to CHK1 can be ...